NCT00267176

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to Ibuprofen 600 mg Three Times a Day in Osteoarthritis Patients With Controlled Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,020 (planned)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: —

Summary

This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.

Conditions

• Osteoarthritis
• Controlled Hypertension

Interventions

Type	Name	Description
DRUG	lumiracoxib

Timeline

• Start date: 2005-11-01
• Primary completion: 2006-09-01
• First posted: 2005-12-20
• Last updated: 2017-02-07

Locations

2 sites across 2 countries: United States, Germany